SCHEMBL8204475

SCHEMBL8204475

O=C1Nc2cc(Br)ccc2Oc2ncccc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
JUN P05412 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
HTR2A P28223 3/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
MCL1 Q07820 1/20 0.39
TGM2 P21980 3/20 0.39
CES1 P23141 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK10 P53779 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9175873 0.84 MAPT (0.58) CYP1A2SMN1; SMN2JUNNFKB1NFKB2
SCHEMBL9178423 0.84 HTR2A (0.54) CYP1A2SMN1; SMN2JUNNFKB1NFKB2
SCHEMBL1367080 0.81 CYP1A2 (0.55) CYP1A2SMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL13343869 0.81 LMNA (0.41) CYP1A2SMN1; SMN2JUNNFKB1NFKB2
SCHEMBL8188282 0.81 ABL1 (0.50) CYP1A2SMN1; SMN2JUNNFKB1NFKB2
SCHEMBL3409888 0.79 AHR (0.49) MAPTALDH1A1TGM2CES1LMNA
SCHEMBL652977 0.73 ABCC4 (0.42) SMN1; SMN2HTR2AMAPTGAALMNA
SCHEMBL7336729 0.73 CYP1A2 (0.55) CYP1A2SMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL11505613 0.70 TGM2 (0.41) MAPTALDH1A1MCL1TGM2CES1
SCHEMBL10392137 0.70 CYP1A2 (0.56) CYP1A2SMN1; SMN2MAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CYP1A2 635/4885SMN1; SMN2 4520/4885JUN 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.